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Consecutive weekly or biweekly serum specimens obtained during a 3- or 4-month study from 16
chimpanzees were examined by immunoblot analyses to identify the immunogenic components of Mycoplasma
pneumoniae. Six experimentally infected chimpanzees showed significant signs of overt disease, including
cough, pharyngitis, rhinitis, fever, and loss of appetite. The sera of these infected chimpanzees recognized from
17 to 20 protein bands. Two control chimpanzees that were not inoculated were included in the study. Three
chimpanzees immunized with a formalin-inactivated OSU-1A vaccine and three chimpanzees immunized with
an experimental acellular vaccine showed minimal signs of disease on challenge. After challenge, the serum
immunoblot responses of the immunized chimpanzees were similar to those of the infected chimpanzees.
Before challenge, the sera of two previously infected chimpanzees recognized protein bands of 169 (which
comigrated with the P1 adhesin), 148, 130, 117, 86, 61, 44, 35, 30, and 29 kDa. After challenge, the previously
infected chimpanzees showed the most intense serum immunoblot responses and were most protected against
colonization and disease. The sera from each of the 16 chimpanzees examined recognized a large number of
immunogenic components, and the serum immunoblot responses were virtually identical to those of patients.
Sera from each chimpanzee and patient recognized 169-, 148-, 130-, 117-, 86-, 44-, and 35-kDa bands and many
of them recognized 67-, 63-, 61-, 56-, 32-, 30-, and 29-kDa protein bands.
The sera examined in this study were collected in two
previous studies (4, 5, 7). In the first study, six chimpanzees
were experimentally infected with Mycoplasma pneumoniae
and showed overt signs of disease that corresponded with peak
lung colonization, the development of cold agglutinins, and
positive X-ray findings (4). The clinical, microbiological, and
serological aspects of the disease were similar to those of
patients with primary atypical pneumonia. Two negative con-
trol chimpanzees that were not inoculated were included in the
study (4). In the second study, three additional chimpanzees
were immunized with an OSU-1A formalin-inactivated vac-
cine, and three were immunized with an experimental acellular
vaccine (5). The six immunized chimpanzees showed less
disease than two unimmunized controls on challenge (5).
The same lot of the OSU-1A formalin-inactivated vaccine
(5) was used earlier in a hamster immunization challenge
potency assay (3) and a human clinical trial (57). The experi-
mental acellular extract vaccine contained attachment, cilio-
toxic, and leukocyte recruitment activities (13, 15), and it
protected immunized hamsters against colonization and the
development of lung lesions on challenge (3). Two chimpan-
zees infected in the first study (4) were challenged in the
second study (5) to determine whether a previous infection
protected against a subsequent challenge. The two previously
infected chimpanzees showed no detectable indication of
disease and were virtually free of colonization.
The purpose of the present study was to identify the
immunogenic components of M. pneumoniae by analyzing and
comparing the immunoblot responses of sera obtained from 16
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chimpanzees that were unimmunized and unprotected, immu-
nized and partially protected, or previously infected and fully
protected on challenge.
MATERIALS AND METHODS
M. pneumoniae. M. pneumoniae PI-1428 was used previously
to experimentally infect guinea pigs (11, 12), hamsters (2, 3),
Cercopithecus (African green) and Macaca (rhesus) monkeys
(28), human volunteers (19, 48, 49), and chimpanzees (4, 5).
Strain PI-1428 was also shown to attach avidly to cell cultures
(14, 17). The organism was grown in a modified Edward-
Hayflick medium containing a rich basal medium, 15% horse
serum, and 5% yeast extract (1). The preparation of the
mycoplasma antigen and the negative antigen control (com-
plete sterile broth medium) used in these studies was described
earlier (27).
Chimpanzees. The treatments and experimental protocols of
the chimpanzees examined (4, 5) are summarized in Table 1.
Although 16 animals were used, two chimpanzees (854 and
881) were used in both studies. They were infected in the first
study and challenged in the second study to determine whether
a previous infection protected against a subsequent challenge.
Vaccines. The same lot of the formalin-inactivated OSU-1A
vaccine used to immunize the group 4 chimpanzees was used
earlier in the human clinical trials (57). Each immunizing dose
contained 1.0 mg of protein suspended in 3 ml of phosphate-
buffered saline (PBS; pH 7.2). The experimental acellular
vaccine administered to the group 5 chimpanzees consisted of
a soluble, protein-rich, acellular extract of virulent strain
PI-1428 of M. pneumoniae that contains attachment, ciliotoxic,
and leukocyte recruitment activities (14, 15) and the P1
adhesin protein. Each immunizing dose consisted of 1.67 mg of
protein dissolved in 3 ml of Hanks balanced salt solution.
Chimpanzee sera. The sera used had been collected earlier
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TABLE 1. Treatment given to the chimpanzees used in the study
Representative
Experimental chimpanzee . Refer-Group treatment identification Figure ence
no.
1 Inoculated with 107 881 1A 4
CCU of M. pneu-
moniae
2 Inoculated with 3 x 107 1028 lB 4
CCU of M. pneu-
moniae
3 Negative controls, inad- 1110 iC 4
vertently infected
4 Immunized with forma- 903 2A 5
lin-inactivate vaccine
and challenged
5 Immunized with acellu- 1008 2B 5
lar vaccine and chal-
lenged
6 Previously infected with 881 2C 5
M. pneumoniae and
challenged
7 Sterile broth instead of 1161 2D 5
vaccine, challenged
and infected
(4, 5). In brief, following inoculation with strain PI-1428, sera
were obtained from the six experimentally infected chimpan-
zees (groups 1 and 2 [Table 1]) and the two negative controls
(group 3) twice a week for the first month and weekly
thereafter for 16 weeks (4). Sera from the six immunized
(groups 4 and 5), two previously infected (group 6), and two
positive control chimpanzees (group 7) were obtained at -5
weeks (before the first immunizing dose), -2 weeks (before
the second immunizing dose), day 0, before challenge, weekly
for the next 4 weeks, and biweekly thereafter for 16 weeks (5).
Although immunoblots were done on each serum sample
collected from each of the 18 treated chimpanzees, the results
are given only for sera obtained at 0, 1, 2, 4, 6, 9, and 12 weeks
for the group 1 to 3 chimpanzees and at -5, -2, 0, 1, 3, 6, 10,
and 16 weeks for the group 4 to 7 chimpanzees. Moreover, the
data presented in this report are given for only one represen-
tative chimpanzee in each of the seven groups (Table 1).
Human sera. Paired acute- and convalescent-phase sera of a
patient with primary atypical pneumonia were kindly supplied
by George Kenny, Seattle, Wash. The diagnosis was based on
a fourfold increase in antibody titer and direct isolation of M.
pneumoniae.
SDS-PAGE and immunoblot analyses. The polypeptide
patterns were examined by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE), as described by Lae-
mmli (43), with 12% nongradient or 10 to 20% gradient gels as
described by us earlier (27, 36). In brief, the protein profiles
were examined with 12% nongradient or 10 to 20% gels (12 by
16 cm) and a total of 500 ,ug of mycoplasma protein. Following
electrophoresis, the proteins were transferred to nitrocellulose
membranes. The nitrocellulose blots were subsequently
stained by ponceau red, air dried, and cut into 5-mm-thick
strips. Each strip was incubated for 3 to 4 h in a standard
blocking solution and then incubated overnight with a 1:100
dilution of serum in the blocking solution. Blots were rinsed
three times (20 min each time) with the blocking solution and
incubated for 4 additional h with "NI-labeled anti-human
immunoglobulin G antibody (1:500). The blots were rinsed
extensively once with blocking solution and three times with
PBS, air dried, and then exposed to film. The anti-human
immunoglobulin G secondary antibody (goat anti-human im-
munoglobulin G Fc fragment [gamma chain specific]) was
labeled with 125I.
RESULTS
Serum immunoblot responses. (i) Experimentally infected
chimpanzees. The serum immunoblot responses of represen-
tative chimpanzee 881 inoculated with 1 x 107 color-changing
units (CCU) (group 1) and representative chimpanzee 1028
inoculated with 3 x 107 CCU (group 2) of strain PI-1428 are
shown in Fig. 1A and B, respectively. Before inoculation, the
sera of five chimpanzees showed no detectable response, but a
sixth chimpanzee, number 957 (group 2), recognized a major
63-kDa band and two minor (56- and 44-kDa) bands (data not
shown). Significant antibody responses were detected within 3
to 4 weeks after challenge, and individual chimpanzees recog-
nized from 14 to 20 protein bands. Serum from each infected
chimpanzee recognized 169-, 148-, 130-, 117-, 86-, 71-, 44-, 35-,
and 30-kDa protein bands, and the sera of most chimpanzees
recognized 80-, 63-, 61-, 56-, 46-, 40-, and 29-kDa bands.
(ii) Noninoculated, negative controls. Although various pre-
cautions were taken to minimize direct contact between the
inoculated group 1A and 1B chimpanzees and the noninocu-
lated control group 1C chimpanzees, the two controls inocu-
lated with sterile broth instead of organisms became inadvert-
ently infected on day 19 (chimpanzee 856) and day 48
(chimpanzee 1110) of the study (4). The serum antibody
responses were similar to, but less intense than, the group 1A
and 1B inoculated chimpanzees. The serum immunoblot re-
sponse of representative chimpanzee 1110 is shown in Fig. 1C.
The control chimpanzees were housed in individual cages
and quartered in a separate room away from the inoculated
chimpanzees. All implements were sterilized before use in
each animal, and aseptic procedures were maintained through-
out the study. Controls were examined first throughout the
study. Despite these precautions, the controls became colo-
nized, developed serum antibody responses, and showed overt
signs of moderate disease. Strains of M. pneumoniae isolated
from the infected controls were indistinguishable from strain
PI-1428 by culture and serologic procedures. Preselection
examinations of these chimpanzees were negative for M.
pneumoniae by culture and serology. In patients, transmission
may develop among military recruits, students, and children
housed in confined quarters (19, 24-26, 31, 48, 49, 57).
Although not determined, the mode of transmission was
probably (i) an aerosol from an inoculated, infected chimpan-
zee to a control; (ii) an aerosol from an inoculated, infected
chimpanzee through a caretaker to a control; or (iii) an
instrument fomite, such as a contaminated bronchoscope. In
the monkey animal model, Friedlaender et al. (28) reported
that control monkeys housed together with cage mates exper-
imentally infected with M. pneumoniae did not become colo-
nized (28). This suggests that chimpanzees may be more
susceptible to infection withM pneumoniae than monkeys are.
Formalin-inactivated vaccine. Serum obtained before im-
munization from chimpanzee 810 (group 4) showed an intense
response to a 61-kDa band and a weak response to a 71-kDa
band (data not shown). Because shock proteins of M. pneu-
moniae range from about 61 to 67 kDa and are related to the
bacterial common antigen (21, 50), strain PI-1428 was tested
against antiserum to a GroEL-like protein of Bordetella pertus-
sis that was kindly provided by J. L. Arciniega, Bethesda, Md.
The antiserum recognized protein bands with approximate
molecular masses of 61, 63, and 67 kDa (data not shown).
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After challenge, the sera of many, but not all, of the 16
chimpanzees recognized bands with similar molecular masses.
Immunization did not induce a significant serum immuno-
blot response. However, after challenge, each immunized
chimpanzee showed an intense antibody response, and the
serum immunoblot patterns were similar to those of the
infected group 1 to 3 chimpanzees. The serum immunoblot
response of representative chimpanzee 903 is shown in Fig. 2A.
Acellular vaccine. Before immunization, serum of chimpan-
zee 918 showed an intense response to a 30-kDa protein band,
and reactivity increased in intensity after challenge (data not
shown). Immunization did not induce a significant serum
antibody response in two of the chimpanzees (group 5), but the
third chimpanzee (number 905) recognized a 67- and a 30-kDa
band that increased in intensity after challenge. After chal-
lenge, the serum antibody responses were similar to those of
group 1 to 4 chimpanzees. The serum immunoblot response of
representative chimpanzee 1108 is shown in Fig. 2B.
Previously infected chimpanzees. Before challenge, the two
previously infected chimpanzees (group 6) showed significant
serum immunoblot responses to 169-, 148-, 130-, 117-, 86-, 61-,
44-, 35-, 30-, and 29-kDa bands. Chimpanzee 854 also recog-
nized a 63- and a 56-kDa band (data not shown). After
challenge, the serum antibody responses were similar to those
of the group I to 5 chimpanzees, but the immunoblot reactions
were much more intense. The previously infected chimpanzees
also produced very intense immunoblot responses to the less
reactive bands, such as the 56-, 32-, 30-, and 29-kDa bands, that
were recognized by some of the other 14 chimpanzees. The
serum immunoblot response of representative chimpanzee 881
is shown in Fig. 2C.
Nonimmunized, positive control chimpanzee. Following
challenge, the serum antibody responses in the group 7 chim-
panzees were similar to those of the group 1 to 5 chimpanzees.
The serum immunoblot response of representative chimpan-
zee 1161 is shown in Fig. 2D.
Patient versus chimpanzee sera. Figure 3 shows the immu-
noblot responses of acute- and convalescent-phase sera of a
patient and the pre- and postchallenge sera of representative
chimpanzee 902 (group 7) and chimpanzee 903 (group 4). The
acute-phase serum of the patient recognized an 86-kDa band,
whereas the prechallenge chimpanzee sera showed no detect-
able response. However, the responses of the chimpanzees
after challenge were virtually identical to those of the conva-
lescent-phase serum of the patient. The serum of each chim-
panzee recognized 169-, 148-, 130-, 117-, 86-, 44-, 35-, and
30-kDa protein bands, and the sera of many chimpanzees
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FIG. 1. Serum immunoblot responses of representative chimpan-
zee 881 (A) experimentally infected with 1 x 107 CCU (group 1),
representative chimpanzee 1028 (B) experimentally infected with 3 x
107 CCU (group 2) of strain PI-1428, and representative chimpanzee
1110 (C), an uninoculated control chimpanzee that became inadvert
The purpose of this study was to compare the serum
immunoblot responses of 16 chimpanzees that were unimmu-
nized and unprotected, immunized and partially protected, or
previously infected and protected from disease on challenge.
Chimpanzees were used because of their close relationship
to humans and because the M. pneumoniae-induced pneumo-
nia in chimpanzees (4) was similar to naturally occurring
primary atypical pneumonia in patients (18, 22, 31, 48). Unlike
the other animals examined, chimpanzees developed cold
agglutinins, positive X-ray findings, and overt signs of disease.
ently infected during the study (group 3). Mr, approximate molecular
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FIG. 2. Serum immunoblot responses of representative chimpanzee 903 (A) immunized with the formalin-inactivated OSU-1A vaccine (group
4), representative chimpanzee 1008 (B) immunized with the experimental acellular vaccine (group 5), representative chimpanzee 881 (C) that was
challenged following a previous infection (group 6), and representative chimpanzee 1161 (D) that was unimmunized and challenged (group 7). Mr,
approximate molecular weights. i.p. and i.t., intraperitoneal and intratracheal inoculation, respectively, of chimpanzees given either vaccine (group
2A and 2B) or sterile broth medium (group D). ch., challenge; Weeks, time at which serum specimens were collected.
In addition to M. pneunioniae, chimpanzees were used to
examine the pathogenicity of several reputed human patho-
gens (6), including Mycoplasma hominis (7), Mycoplasma geni-
talium (52, 54, 55), and Ureaplasma urealyticlum (7, 53). In each
of these studies, the infections induced in chimpanzees have
best reflected the course of the disease in humans. For these
reasons, the chimpanzee was selected for the present study in
an attempt to identify the immunogenic components of M.
pneumoniae, and the results indicate that the serum immuno-
blot responses obtained with chimpanzees were virtually iden-
tical to those of patients (56).
Except for the previously infected chimpanzees, the immu-
noblot responses before treatment were mostly negative, with
few exceptions. The sera of several chimpanzees recognized
67-, 63-, 61-, 56-, 44-, and/or 30-kDa bands before treatment.
The serum immunoblot responses after immunization were
also mostly negative, with few exceptions. After immunization,
chimpanzee 905 (acellular vaccine) recognized a 67- and a
30-kDa band, and reactivity to these bands increased in
intensity after challenge.
Before challenge, the two previously infected chimpanzees
recognized 169-, 148-, 130-, 117-, 86-, 61-, 44-, 35-, 30-, and
29-kDa protein bands. After challenge, these chimpanzees
showed the most intensive serum immunoblot responses and
were most protected against colonization and disease (5). The
same sera also showed intense serum antibody responses by
the metabolism inhibition procedure (5). Hamsters that were
previously infected with M. pneumoniae also showed intense
serum metabolism inhibition antibody responses after chal-
lenge, and they were protected against colonization and the
development of histologic lung disease (3). Most patients are
protected against reinfection, but immunity is considered to be
short-lived (24-26). Because a previous infection can elicit a
protective immune response, immunization should provide a
A
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FIG. 3. Serum immunoblots of chimpanzee 902 (group 7) before
(lane 1) and after (lane 2) challenge, chimpanzee 903 (group 4) before
(lane 3) and after (lane 4) challenge, and the acute-phase (lane 5) and
convalescent-phase (Conv) (lane 6) sera of a patient with naturally
occurring M. pneumoniae pneumonia. SR, standard reference molec-
ular weight markers; and Mr, approximate molecular weights.
viable approach to the prevention of disease if the immuno-
gen(s) is presented by an optimal route(s).
The ability of a strain to attach to target cells in vitro (14, 17,
45) has been correlated with the ability of that strain to
produce disease in hamsters (3). Attachment of M pneu-
moniae to the respiratory epithelium is mediated by a special-
ized terminal tip apparatus, and the 169-kDa P1 adhesin
protein was shown to be located on the terminal tip (33).
Protease treatment resulted in the loss of P1 and the ability to
attach and to produce disease. The regeneration of the P1
restored the ability to attach and to produce disease (32, 45).
Antibody specific for the P1 has been detected in convalescent-
phase sera of guinea pigs (38) and patients (36, 56, 58), and the
P1 adhesin protein has been considered an important immuno-
gen (33-36, 38, 44, 51, 56). In this study, the 169-kDa protein
band (that migrated with the P1 adhesin) was recognized by
serum obtained from each of the 16 chimpanzees examined.
However, attachment appears to be a complex phenomenon,
and several factors are involved in adherence (8-10, 20, 23, 29,
30, 32, 37, 39-41, 45, 58). By one-dimensional gel analysis,
pathogenic strain M129-B7 and its isogenic nonpathogenic
strain M129-B169 have identical protein profiles. By immuno-
blot analysis, the nonpathogenic strain M129-B169 does not
possess the 90- and 40-kDa proteins (35, 44, 45, 51), and it lost
the ability to attach (14, 17, 45) and to produce disease (3).
Franzoso et al. (27) showed that the 35- and the 86-kDa
proteins identified by us were similar or identical to the 90- and
the 40-kDa proteins identified by Hu et al. (35) and by
Herrmann and colleagues (44, 51). Franzoso et al. (27) also
showed that the 86 (90)- and 35 (40)-kDa proteins were
present in each of three pathogenic strains ofM pneumoniae
but were absent in the nonpathogenic strain M129-B169 (27).
In addition, the 86- and 35-kDa proteins were surface-exposed,
membrane-integrated components localized on the terminal
tip apparatus (27). Because the 86 (90)- and 35 (40)-kDa
proteins are highly conserved among pathogenic, cytadsorbing
strains, these components may be important virulence factors.
In the present study, the 86- and 35-kDa protein bands were
highly immunogenic and were recognized by serum obtained
from each of the 16 chimpanzees examined.
Yayoshi et al. (58) reported that the convalescent-phase sera
of their patient group showed intense immunoblot reactions
with the 168- and the 85-kDa protein bands when tested
against pathogenic strains but not when tested against non-
pathogenic strains. Vu et al. (56) examined freshly isolated
strains of M. pneumoniae from 12 patients for antigenic
variation by immunoblot analysis. By using the homologous
strain isolated and the homologous convalescent-phase serum,
each patient recognized the same five (170-, 130-, 90-, 45-, and
35-kDa) protein bands. In this study, serum obtained from
each chimpanzee examined recognized similar or identical
protein bands.
Several other components of M. pneumoniae have been
associated with adherence. Geary et al. (29, 30) identified a
32-kDa binding protein, and Baseman and colleagues reported
that the 30-kDa protein (P30) adhesin that they identified was
localized at the terminal tip structure (8-10, 20, 32, 39-41). In
this study, serum from virtually each chimpanzee examined
recognized a 30- and a 29-kDa protein band in pathogenic
strain PI-1428. Madsen et al. (46) reported that a polypeptide
with a molecular weight of 43,000 appeared to be a major
component of M. pneumoniae; using a monoclonal antibody
against this component, they showed that it reacted with each
of 33 different clinical isolates. In this study, whereas the
43-kDa region is not very prominent in other infected animals,
the serum obtiined from each of the 16 chimpanzees examined
recognized a prominent band in the 44-kDa region. In the
extensive study of serum of patients infected with M. pneu-
moniae (56), this region was recognized by all of the human
convalescent-phase serum samples obtained from the 12 pa-
tients tested. Under the conditions of our test procedures, it is
possible that the 29-, the 30-, and the 44-kDa protein bands
identified by us correspond to the 30-, the 32-, and the 43-kDa
proteins, respectively, identified by these other investigators.
However, this remains to be determined, since comparative
studies were not done.
M. pneumoniae attaches to sulfated glycoconjugates (42),
and two proteins (56 and 32 kDa) have been implicated in
attachment to sulfated glycoconjugates. Marcus et al. (47)
showed that the 56-kDa protein was an integral membrane
protein by surface proteolysis, Triton X-114 partitioning, and
immunoblots of membrane preparations with a monoclonal
antibody described previously (16). Using immunoelectron
microscopy, Marcus et al. (47) also showed that the 56-kDa
protein was localized on the neck of the tip structure of M.
pneumoniae. Many of the chimpanzees examined in this study
also recognized a band with an approximate molecular mass of
56 kDa.
In summary, these findings indicate that the serum immu-
noblot responses of the 18 treated chimpanzees examined were
very similar to those of the human convalescent-phase serum
samples of the 12 patients tested with naturally occurring
disease as reported by Vu et al. (56). We have also shown that
the pathogenic strain PI-1428 of M. pneumoniae possesses a
large number of immunogenic components. These include
protein bands with approximate molecular masses of 169, 148,
130, 117, 86, 56, 35, 30 to 32, and 29 to 30 kDa. Therefore, it
seems reasonable to suggest that, in addition to the P1 adhesin,
a number of other immunogenic proteins might represent
potentially important immunogens and that some of these
components should also be considered as possible candidates
for inclusion in the development of purified acellular vaccines
for prevention of M. pneumoniae disease.
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